PURVI AMIN: Open Payments
NPI 1942604798 · ORANGE CITY, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,579 in 78 payments from 16 companies in 2025. Trend: 2023 $1,410 · 2024 $1,839 · 2025 $1,579
Food & beverage: $1,502Education: $77
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 17 | $348 |
| ABBVIE INC. | 15 | $292 |
| Lilly USA, LLC | 8 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $135 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $115 |
| Aimmune Therapeutics, Inc. | 4 | $107 |
| PFIZER INC. | 4 | $78 |
| Madrigal Pharmaceuticals | 3 | $68 |
| Ipsen Biopharmaceuticals, Inc | 2 | $53 |
| Novo Nordisk Inc | 2 | $48 |
Products named: TREMFYA, SKYRIZI, OMVOH, XIFAXAN, ZENPEP, ENTYVIO, REZDIFFRA, RINVOQ.
Industry payments across FL — which companies pay providers there.
